Combined Shareholders’ Meeting of 7 June 2017
Combined Shareholders’ Meeting of 7 June 2017
Combined Shareholders’ Meeting of 7 June 2017
- 07 June 2017 - 0 mins read
Related Press Releases
![Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
21 August 2023
15 mins read
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
![Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
01 June 2023
1 mins read
Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan
![Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
01 June 2023
2 mins read
Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023
![Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023 Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
31 May 2023
4 mins read
Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023
![Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
02 March 2023
9 mins read
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
![Combined Shareholders’ Meeting of 24 May 2022 Combined Shareholders’ Meeting of 24 May 2022](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
03 May 2022
2 mins read
Combined Shareholders’ Meeting of 24 May 2022
![Combined Shareholders’ Meeting of 30 May 2018 Combined Shareholders’ Meeting of 30 May 2018](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
30 May 2018
1 mins read